433 related articles for article (PubMed ID: 20052757)
21. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Binder G
Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
[TBL] [Abstract][Full Text] [Related]
22. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
[TBL] [Abstract][Full Text] [Related]
23. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Swanson KD; Winter JM; Reis M; Bentires-Alj M; Greulich H; Grewal R; Hruban RH; Yeo CJ; Yassin Y; Iartchouk O; Montgomery K; Whitman SP; Caligiuri MA; Loh ML; Gilliland DG; Look AT; Kucherlapati R; Kern SE; Meyerson M; Neel BG
Genes Chromosomes Cancer; 2008 Mar; 47(3):253-9. PubMed ID: 18064648
[TBL] [Abstract][Full Text] [Related]
24. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
25. [Cardiofaciocutaneous syndrome, a Noonan syndrome related disorder: clinical and molecular findings in 11 patients].
Carcavilla A; García-Miñaúr S; Pérez-Aytés A; Vendrell T; Pinto I; Guillén-Navarro E; González-Meneses A; Aoki Y; Grinberg D; Ezquieta B
Med Clin (Barc); 2015 Jan; 144(2):67-72. PubMed ID: 25194980
[TBL] [Abstract][Full Text] [Related]
26. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Ogata T; Yoshida R
Pediatr Endocrinol Rev; 2005 Jun; 2(4):669-74. PubMed ID: 16208280
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
[TBL] [Abstract][Full Text] [Related]
28. [New findings in Noonan syndrome and Leopard syndrome: activating mutations in RAF-1 and SOS-1].
Dereure O
Ann Dermatol Venereol; 2008; 135(8-9):624-5. PubMed ID: 18789305
[No Abstract] [Full Text] [Related]
29. [RAS/MAPK signal transduction pathway and its role in the pathogenesis of Noonan syndrome].
Gos M; Leszkiewicz M; Abramowicz A
Postepy Biochem; 2012; 58(3):255-64. PubMed ID: 23373411
[TBL] [Abstract][Full Text] [Related]
30. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
31. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.
Denayer E; Devriendt K; de Ravel T; Van Buggenhout G; Smeets E; Francois I; Sznajer Y; Craen M; Leventopoulos G; Mutesa L; Vandecasseye W; Massa G; Kayserili H; Sciot R; Fryns JP; Legius E
Genes Chromosomes Cancer; 2010 Mar; 49(3):242-52. PubMed ID: 19953625
[TBL] [Abstract][Full Text] [Related]
32. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
33. Genetic and pathogenetic aspects of Noonan syndrome and related disorders.
Zenker M
Horm Res; 2009 Dec; 72 Suppl 2():57-63. PubMed ID: 20029240
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
Ferreira LV; Souza SC; Montenegro LR; Malaquias AC; Arnhold IJ; Mendonca BB; Jorge AA
Clin Endocrinol (Oxf); 2008 Sep; 69(3):426-31. PubMed ID: 18331608
[TBL] [Abstract][Full Text] [Related]
35. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
[TBL] [Abstract][Full Text] [Related]
36. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
[TBL] [Abstract][Full Text] [Related]
37. Orthopaedic conditions in Ras/MAPK related disorders.
Reinker KA; Stevenson DA; Tsung A
J Pediatr Orthop; 2011; 31(5):599-605. PubMed ID: 21654472
[TBL] [Abstract][Full Text] [Related]
38. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
Savage MO; Padidela R; Kirk JM; Malaquias AC; Jorge AA
Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
[TBL] [Abstract][Full Text] [Related]
39. Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
Uludağ Alkaya D; Lissewski C; Yeşil G; Zenker M; Tüysüz B
Am J Med Genet A; 2021 Dec; 185(12):3623-3633. PubMed ID: 34184824
[TBL] [Abstract][Full Text] [Related]
40. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.
Papadopoulos G; Papadopoulou A; Kosma K; Papadimitriou A; Papaevangelou V; Kanaka-Gantenbein C; Bountouvi E; Kitsiou-Tzeli S
Eur J Pediatr; 2022 Oct; 181(10):3691-3700. PubMed ID: 35904599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
